TScan Therapeutics, Inc. · NASDAQ:TCRX
TScan Therapeutics — Tandem Meetings 2025
14 slides from TScan Therapeutics's conference presentation, February 2025
Slide 1: TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-free Survival
TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 ALLOHA Trial Monzr M. Al Malki, MD1, Alla Keyzner, MD2,
Slide 2: Relapse after hematopoietic cell transplant remains an unmet need
Relapse after hematopoietic cell transplant remains an unmet need • Allogeneic hematopoietic cell transplantation (HCT) can cure some patients with AML, ALL or MDS • Advances in reduced intensity conditioning (RIC-HCT) regimens as well as GvHD prophylaxis with post-transplant cyclophosphamide (PTCy)
Slide 3: TSC-100 and TSC-101 are adjuvant engineered TCR-T cells designed to eliminate residual recipient cells
TSC-100 and TSC-101 are adjuvant engineered TCR-T cells designed to eliminate residual recipient cells and prevent relapse following HCT POST-TRANSPLANT PATIENT PATIENT HA-1 or HA-2 Cancer positive Residual cell HA-1 or HA-2 cancer Residual Conditioning cancer negative HA-1 or HA-2 therapy Prevent p
Slide 4: Multi-arm Phase 1 trial for TSC-100 & TSC-101 in subjects with AML, ALL, and MDS
Multi-arm Phase 1 trial for TSC-100 & TSC-101 in subjects with AML, ALL, and MDS Treatment Arms Control Arm Transplant Transplant + TSC-100 + TSC-101 Transplant Alone (HA-1 positive) (HA-2 positive) Manufacturing TSC-100 or TSC-101 TSC-100 or TSC-101 apheresis Infusion 1 Infusion 2 Subject Donor HCT
Slide 5: Majority of subjects in the treatment and control arms are at high risk for relapse
Majority of subjects in the treatment and control arms are at high risk for relapse TSC-100 TSC-101 Any TSC Control Subjects Enrolled and assigned 14 12 26 13 Subjects Transplanted (efficacy data cohort) 14 12 26 12 Subjects Infused (safety data cohort) 10 12 22 N/A* Median Time of Follow Up, months
Slide 6: Subjects treated at all three dose levels with no dose-limiting toxicities
Subjects treated at all three dose levels with no dose-limiting toxicities Planned Day of Infusion Post HCT TSC 100 TSC 101 Dose Level +21 +61 N=10 N=12 DL1 5×106 TCR-T cells/kg N/A 1 1 DL2 5×106 TCR-T cells/kg 5×106 TCR-T cells/kg 1 2 DL3 5×106 TCR-T cells/kg 20×106 TCR-T cells/kg 8 9 6 As of Nov 2
Slide 7: TSC-100 and TSC-101 TCR-T cells detected for > 1-year with increased persistence at highest dose level
TSC-100 and TSC-101 TCR-T cells detected for > 1-year with increased persistence seen at highest dose level (DL3) TSC persistence over time TSC-100 TSC-101 15 15 15 Dose Level 1 Dose Level 2 Dose Level 3 TSC-100/TSC-101 - % of peripheral T cells TSC-100/TSC-101 - % of peripheral T cells TSC-100/TSC-
Slide 8: Adverse events of special interest were low grade and manageable
Adverse events of special interest were low grade and manageable • Balanced Grade II – IV acute GvHD TSC-100 TSC-101 Any TSC Control Adverse Event of Special Interest* n=10 n=12 n=22 n=12 between treatment and control arms Any Acute GvHD** 5 (50%) 6 (50%) 11 (50%) 4 (33%) • No cases of moderate or s
Slide 9: Grade >3 treatment emergent adverse events are consistent with transplantation
Grade >3 treatment emergent adverse events are consistent with transplantation Any TSC Control Events in >5% of subjects n=22 n=12 Anemia 7 (31.8) 2 (16.7) Platelet count decreased 4 (18.2) 3 (25.0) Neutrophil count decreased 3 (13.6) 1 (8.3) Pneumonia 3 (13.6) 1 (8.3) Sepsis 3 (13.6) 0 Decreased ap
Slide 10: TCR-T infusion is associated with fewer relapses
TCR-T infusion is associated with fewer relapses Control arm 4 of 12 (33%) 0.40 Probability of relapse 0.30 0.20 Treatment arm 2 of 26 (8%) 0.10 HR = 0.28, p=0.14 0.00 0 45 90 135 180 225 270 315 360 405 450 495 540 585 630 675 720 765 Days post HCT Number at risk Control arm 12 11 9 9 5 4 4 4 4 2 2
Slide 11: Event-free survival (EFS) favors the treatment arm
Event-free survival (EFS) favors the treatment arm 1.00 Treatment arm 0.75 EFS probability 6 of 26 (23%) 0.50 Control arm 7 of 12 (58%) 0.25 HR = 0.30, p=0.04 0.00 0 60 120 180 240 300 360 420 480 540 600 Days post HCT Number at risk Control arm 12 11 7 3 2 2 2 0 0 0 0 Treatment arm 26 23 17 12 10 8
Slide 12: Complete donor chimerism achieved in all patients after initial TSC infusion
Complete donor chimerism achieved in all patients after initial TSC infusion TSC-100/TSC-101 Treatment-arm subjects Control-arm subjects Infused with TSC 101 100 101 100 101 100 101 100 101 100 101 101 101 100 100 101 100 101 100 100 100 100 C1 C2 C3 C4 C5 C6 C7 C8 C 9 C 10 C 11 C 12 Time DL1 DL1 DL
Slide 13: MRD negativity achieved in all treatment-arm subjects
MRD negativity achieved in all treatment-arm subjects Pre-HCT Arm Disease 6 months 12 months 24 months MRD TSC-101 DL 1 MDS p53mP-004-0001 TSC-100 DL1 T-ALL P-004-0004 X TSC-101 DL2s‡ AML P-004-0005 TSC-100 DL2 AML P-007-0002 TSC-100/TSC-101 infusion TSC-101 DL2 B-ALL P-004-0006 TSC-100 DL3 AML P-00
Slide 14: Summary
Summary • Infusions with TSC-100 and TSC-101 were well-tolerated with no DLTs and adverse events consistent with HCT • TSC-100 and TSC-101 TCR-T cells have been detected > 1-year post infusion and have a clear dose- persistence relationship • 2 of 26 (8%) treatment-arm subjects relapsed as compared